FDA-approved naltrexone, in a low dose, can boost the
immune system — helping those with HIV/AIDS, cancer,
autoimmune diseases, and central nervous system disorders.
First Study of LDN Published in US Medical Journal
Dr. Jill Smith’s original article, "Low-Dose Naltrexone Therapy Improves Active Crohn’s Disease," in the January issue of the American Journal of Gastroenterology (2007;102:1–9), officially presents LDN to the world of scientific medicine. Smith, Professor of Gastroenterology at Pennsylvania State University's College of Medicine, found that two-thirds of the patients in her pilot study went into remission and fully 89% of the group responded to treatment to some degree. She concluded that “LDN therapy appears effective and safe in subjects with active Crohn’s disease.” (For further information on Smith's study, please see the linked Clinical Trials page.)
This was so exciting to me. If you are interested on other information please click HERE and you will be taken to the LDN Home Page.
Hope this makes you all smile!